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EFFECTS OF ASPIRIN AND ITS DERIVATIVES IN COMBINATION WITH 
ELECTROPORATION FOR DRUG DELIVERY IN CULTURED CELLS 
Jennifer Langham 
ABSTRACT 
 
 The purpose of this research was to investigate the effects that aspirin (ASA) and 
its metabolites, salicylic acid (SA) and acetic acid (AA), have on the delivery of drugs 
across biological barriers when used in conjunction with electroporation.  Electroporation 
is a technique used to enhance drug delivery across bio-membranes in which a 
transmembrane potential is induced into cellular membranes, resulting in the creation of 
aqueous pores that allow molecules to pass through the otherwise impermeable barrier.   
Aspirin is a widely used drug that has been used for over a century and has been proven 
relatively safe at normal doses as indicated by the low number of reports of poisoning 
cases it has been involved in.  Components of aspirin are known to soften the cellular 
membranes by solubilizing the cell’s surface proteins. 
 B16F10 murine melanoma cancer cells were used in this investigation and treated 
with a 120µM buffered solution of calcein, a fluorescent indicator, in which the amount 
of delivered tracer molecules was measured using fluorescence.  Identical concentrations 
of ASA and SA were investigated (1mM, 5mM, and 10mM) separately, focusing the 
effects concentration has electroporation delivery.  Diluted acetic acid was also 
 vi
investigated at pH values of 6.42, 5.36, and 4.40.  The concentration of acetic acid that 
had the lowest pH and ASA with the highest concentration had the greatest impacts on 
the augmentation of calcein delivery.  Therefore, this demonstrates that aspirin and acetic 
acid have the potential to improve targeted molecular delivery in combination with 
electroporation. 
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CHAPTER 1:  INTRODUCTION 
 
1.1 Introduction to Drug Delivery by Electroporation 
Electroporation (E.P.) is a phenomenon in which biomembranes can enter a state 
of reversible electrical breakdown (REB) which allows external molecules to pass 
through the otherwise impermeable lipid phase of the cell membrane.  REB is typically 
induced by applying an electrical potential to the cells which results in a temporary 
destabilization of the cell membrane and permeation through aqueous-filled pore 
openings [1, 2].  The transmembrane potential needed to rupture through a membrane 
bilayer is referred to as the electroporation threshold [3].  Although the mechanism by 
which this phenomenon occurs is not understood in its entirety, it is known that E.P. is 
the direct result of an induced transmembrane potential that is caused by the applied 
electric field [4].  Figure 1.1 shows the induced transmembrane potential in a cell 
exposed to electroporation.  Pores form in regions of the membrane where the induced 
potential is large.  Membrane resealing is a crucial phenomenon of electroporation.  The 
level of membrane recovery is dependent on the amplitude and length of the applied 
pulses because there is a critical range in which the cell can undergo lysis, often referred 
to as irreversible membrane permeabilization [5].  The transient aqueous pore theory 
describes the combined effects of the electric field across a membrane and the associated 
thermal fluctuations [1, 2].  During the destabilization period, the cell membrane is highly 
permeable to exogenous molecules present in the surrounding media. 
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Figure 1.1  Transmembrane Potential Induced in a Spherical Cell by an External Electric Field [4] 
 
There are several parameters that affect electroporation as well as the recovery of 
the membrane such as temperature [6], waveform parameters, the composition of the 
bilayer membrane and ionic and osmotic conditions [7, 8].  One of the most important 
parameters is the electric field strength, E, which is inversely proportional to the distance 
between the electrodes, d, with an applied voltage, V, (E = V/d).  As the voltage is 
increased, the induced transmembrane potential is raised [4].  The result is the creation of 
pores and pore expansion due to structural alterations.  In the case of an isolated spherical 
membrane, this phenomenon is described by the derived equation [9, 10]: 
∆ψ(t) = 1.5E(t)acosθ,  
where ∆ψ is the induced transmembrane potential, θ is the angle between the applied 
electric field and the site on the membrane at which the potential is measured, and a is the 
radius of the cell.  Once the membrane becomes porous, further increase in ∆ψ is 
counteracted by the ionic current through the pores [4]. 
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Another critical parameter is the pulse time τ, which is derived from the total 
circuit resistance, R, and the capacitance, C, between the electrodes (τ = R×C).  The pulse 
time is a major indication of how long the pores will stay opened.  For mammalian cells, 
optimal pulse times have been found to range from tens of microseconds to milliseconds 
[11, 12].  Joule heating occurs as electrical current is applied and is linearly related to the 
square of the field intensity and pulse duration [13].  This condition is easier to control in 
in vitro studies by using a low ionic content pulsing buffer, whereas in in vivo studies, 
local heating is more difficult to avoid; therefore, by applying shorter pulse lengths, this 
effect can be minimized.   
Electroporation has the potential to be used in biotechnological applications both 
in vivo and in vitro.  Though many in vivo applications originate from in vitro 
experimentation, there are a variety of in vitro examples that capitalize on the effects of 
electroporation.  These include loading genetic material and pharmaceutical drugs into 
cells, membrane protein insertion, and clinical applications such as cell-cell and cell-
tissue fusion.  Electroporation of tissue has recently become popular in the medical field 
due to its many possible applications such as cancer tumor therapy [14, 15], localized 
gene therapy [11, 16-18], and transdermal drug delivery [19, 20]. 
Electrochemotherapy is a novel therapy approach to enhance delivery of non-
permeant chemotherapeutic agents to the cytosol of cells, with the assistance of locally 
applied electric fields to temporarily destabilize cell membranes.  This form of therapy 
has shown to be effective in clinical trials for the treatment of tumors including 
melanoma, head and neck squamous cell carcinoma, basal cell carcinoma, Kaposi’s 
sarcoma and adenocarcinoma [14, 15]. 
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Gene therapy is a rapidly growing biotechnological field in which a gene delivery 
problem exists.  The development of gene transfer methods (both in vivo and in vitro) 
include either the biological delivery approach of viral vectors or non-viral methods that 
involve chemical techniques such as lipofection [21], or physical techniques such as 
electroporation and gene gun transfection.  Viral vectors are considered the most widely 
used method for transfection [9] but are often associated with immune responses; 
therefore, continued research in non-viral techniques is essential in order to enhance 
efficiency.  In one study designed to compare the efficiency of in vivo, non-viral gene 
transfer methods, electroporation was found to be as successful and promising as 
lipofection, gene gun and direct DNA injection methods [11]. 
Transdermal delivery of drugs is yet another widely explored topic of in vivo 
electroporation applications.  This route of delivery is a useful alternative to the several 
conventional routes of administration such as orals or injectables because it avoids 
degradation in the gastrointestinal tract and first-pass hepatic metabolism.  Metoprolol, (a 
beta blocker) used in the treatment of angina, has shown successful results in a study 
investigating the mechanisms behind improved transdermal drug delivery by 
electroporation [19].  Reversible skin permeability, electrophoretic movement of the drug 
into the skin with applied pulses, and drug release from the skin reservoir as a result of 
electroporation are examples of mechanisms that link the linear correlation between pulse 
voltage and the quantity of drug delivered [4, 20].   
Examples of in vivo electroporation applications include clinical treatments not 
only for humans, but for animals also.  In a recent study [22], plasmid DNA encoding 
mycobacterial antigens was injected into the muscles of farm animals that are frequently 
 5
infected with Mycobacterium bovis. This bacterium causes bovine tuberculosis.  It has 
been estimated that the economic losses due to tuberculosis in infected cattle alone is $3 
billion annually.  The DNA vaccine delivered by electroporation was reported to protect 
against bovine TB.  The results from the study revealed an increased humoral immune 
response in goats and improved T-cell responses in cattle after the DNA vaccine was 
delivered using E.P.   When compared to animals that did not receive electroporation, the 
vaccine was much more successful.   
Unfortunately, there are undesirable side effects that are contributed to high-
voltage permeation such as irreversible cellular damage [23].  Troiano et al [24] showed 
that by altering the cell’s membrane, excessive damage to the cell may be prevented.  The 
authors of the study added the nonionic surfactant, octaethyleneglycol mono n-dodecyl 
ether (C12E8) to absorb into a lipid bilayer membrane and found that using various 
concentrations of the surface active agent allowed electroporation at lower intensities 
and/or shorter pulse durations to reduce the electroporation threshold. 
Surfactants are typically used in pharmaceuticals to provide increasing 
distribution and penetration to the cell’s membrane by influencing the rate and extent of 
absorption of certain drugs.  Though it has been shown that high concentrations of 
surfactants promote toxicity to the cell’s structure by causing lysis and other irreversible 
damage to the membrane, Lee et al [25] has provided evidence that supports the use of 
the nonionic surface active agent poloxamer 188 (P188) in restoring electrical damage 
and resealing of electropermeabilized cells.  Another group of scientists [26] concluded 
that co-injection of P188 with plasmid DNA helped facilitate gene transfer in skeletal 
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muscles, which supports one application of using surfactants as an excipient for 
intramuscular delivery of ions or water soluble species including drugs or naked DNA. 
 Just as surface-active agents are capable of solubilizing cell membranes, many 
pharmaceutical agents share the same phenomena by interacting with membranes due to 
their physiochemical properties.  Amphiphilic, or hydrophobic, molecules undergo 
various mechanisms of self-association whose main site of action is by rapidly 
permeating the plasma membrane and/or accumulating in the hydrophobic interior of the 
lipid bilayer.  They have been reported to self-associate and bind to the membranes first, 
causing disruption and solubilization, very similar to the action of detergents [27]. 
Amphiphilic compounds contain either an ionic or non-ionic polar head group 
with a hydrophobic portion.  These properties allow the compounds to organize 
themselves as micelles or bilayers.  Their molecular shape and hydrophilic-lipophilic 
balance (HLB) are factors that determine their tendency to form other structures which 
often is a function of pH, temperature, ionic strength, and concentration. 
 
1.2 Aspirin and Its Derivatives 
The structure of aspirin and two of its derivatives, acetic acid and salicylic acid, 
are shown in Figure 1.2.  Aspirin and salicylic acid are hydrophobic compounds.  When 
aspirin is exposed to water or moisture it will begin to hydrolyze, resulting in salicylic 
acid and acetic acid.  The rate of hydrolysis that aspirin may undergo once dissolved in a 
basic solution is second order because it is dependent not only on the aspirin 
concentration, but on the pH of the solution [28]. 
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Figure 1.2  Chemical Structures of (a) Salicylic Acid (b) Acetylsalicylic Acid and (c) Acetic Acid [29] 
 
1.2.1  Properties of Salicylic Acid 
Salicylic acid is a crystalline organic carboxylic acid that is derived from the bark 
of the willow tree.  Willow bark had been used for centuries in folk medicine in certain 
parts of the world as a pain relief treatment.  It is soluble in alcohol, but only slightly 
soluble in water.  It was thought to be too tough on the stomach, therefore it was reacted 
with acetic anhydryde as a buffering agent.  In 1897, the German chemist and employee 
of Friedrich Bayer & Co., Felix Hoffman, was the first to market the buffered form of 
salicylic acid called acetylsalicylic acid [30].   
Salicylic acid is thought to act by solubilizing the cell proteins that keep the 
stratum corneum intact, resulting in desquamation.  Salicylic acid and its derivatives are 
toxic when consumed in large amounts, but is a popular choice as a beta hydroxy acid for 
acne-prone skin care, especially those with sensitive skin.  Mixtures composed of 1-2%, 
aids in effectively penetrating and exfoliating the pores in the skin due to its larger 
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molecular size compared to its cousin, alpha hydroxy acid.  At concentrations of 3-6%, it 
can begin to promote the skin to scale or peel off.  A 50% concentration is used to 
eradicate warts and calluses, due to its tendency to destroy tissue at higher strengths [31]. 
 
1.2.2 Properties of Acetylsalicylic Acid 
Acetylsalicylic acid, commonly known as aspirin is a derivative of salicylic acid.  
In the formation of ASA, the hydroxyl group of SA reacts with acetic anhydride, with 
sulfuric acid as a catalyst.  In this condensation reaction, aspirin and acetic acid are the 
products.  Repeated recrystallization is an effective purification method for impurities 
such as unreacted salicylic acid [29]. 
Aspirin is the acetate ester of salicylic acid, therefore it will hydrolyze to form 
acetic acid and salicylic acid.  Both products are present to some extent in aspirin and a 
measure of their concentration can be indicative of the extent of hydrolysis, which will 
occur when aspirin is added to basic solutions with a pH of greater than 7.4 [20].  Its 
solubility in PBS (pH 7.2) is at least 3 mg/mL and is recommended to use within 30 
minutes of preparation [28].   
There is a wide variety of uses for aspirin, and is continuously investigated for 
more uses.  Some indications include, but not limited to, the use as an analgesic, anti-
inflammatory, antipyretic, anticoagulant and antirheumatic.  It reduces fever by causing 
the blood vessels in the skin to dilate, allowing heat from the body to leave more rapidly 
[30].  It is also used as an additive in food, animal feed, drugs and cosmetics, and is now 
the active ingredient in more than 50 over-the-counter preparations. 
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1.2.3 Properties of Acetic Acid 
Acetic acid is a clear, colorless chemical compound that is responsible for the 
characteristic odor and sour taste of vinegar.  Glacial, or ice-like, acetic acid has a boiling 
point of 118°C, with a density of 1.049 g/ml at 25°C, and a flash point of 39°C.  Its 
freezing point is 16.7°C, slightly lower than room temperature.  It is classified as a weak 
acid due to its ability to not dissociate into its component ions when dissolved in aqueous 
solutions.  Highly concentrated solutions of acetic acid are extremely corrosive, which 
can result in burns if contacted with skin surfaces [32]. 
Acetic acid is a derivative of aspirin, as mentioned earlier, and has several other 
pharmaceutical indications for both adults and children.  When used topically, it can be 
useful for treating fungal infections, wound care (0.25% to 20% concentrations), 
iontophoreisis (2% to 5% concentrations), in diagnostic testing (3% to 5% 
concentrations) such as during a colposcopy or cervicoscopy, and for the use of otitis 
externa (for adults and pediatrics).  At concentrations of 2%, acetic acid is often used as a 
household disinfectant, and is an effective method for cleaning and disinfecting 
respiratory equipment used in the care of cystic fibrosis.  Acetic acid is also often used 
for urinary tract irrigations at a concentration of 0.25% [32]. 
A high-dose intra-tumoral acetic acid injection, for the treatment of hepatocellular 
carcinoma (HCC), is another form of acetic acid therapy.  This method of injecting 3 to 5 
ml of a 50% concentration solution has shown to effectively treat fewer than 4 small (< 
3cm diameter) lesions.  This treatment has been investigated for over a decade and when 
compared to a similar method, percutaneous ethanol injection (PEI) therapy, the acetic 
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acid injection has shown to be superior in that it has a lower recurrence rate of lesions 
(8% vs. 37%) and a higher 2-year survival rate of patients (92% vs. 63%) [33, 34].   
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CHAPTER 2:  RESEARCH GOALS 
   
It is clear that electroporation is an established and effective method of delivering 
molecules to cells.  E.P. has proven to affect cellular membranes in many in vivo and in 
vitro biotechnological applications, which include treatments in humans and animals 
alike.  The need for research to enhance the delivery of drugs, genetic material, vaccines, 
and other molecules beyond the established capabilities of electroporation is essential in 
the medical field.  The benefits of electroporation come with some undesirable side 
effects.  Irreversible damage to tissues and cells occur as a result of electrical stimuli.       
The use of surfactants in combination with electroporation delivery has been 
explored because it can allow for lower electrical thresholds and shorter pulse durations.  
The addition of low concentrations of surfactants has also shown to enhance the 
permeation of molecules through cellular membranes.  It has even been reported that 
certain surfactants can help restore electrical damage to membranes.  Similar properties 
of surfactants exist in some pharmaceutical drugs categorized as amphiphilic, or 
hydrophobic compounds.  These drugs have the potential to assist in the treatment of 
electroporation by enhancing the disruption of membranes and the formation of aqueous 
pathways, resulting in more efficient molecule delivery.   
The purpose of this study was to determine the effects that aspirin and two of its 
derived components have on the delivery of molecules through the cell membrane alone 
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and in combination with electroporation treatment.  Concentration and pH are factors that 
were investigated as well as the extent of recovery and swelling of cell membranes.  The 
results are intended to provide insight to the potential of improving molecular delivery by 
electroporation.  This study was designed specifically to determine if:   
• ASA or 2 of its derivatives could facilitate molecular uptake through the cell 
membrane  
 
• ASA and its derivatives could augment electroporation mediated delivery of non-
permeant molecules 
  
• cell membranes recover from treatment with ASA and its derivatives alone and 
when coupled with electroporation. 
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CHAPTER 3:  MATERIALS & METHODS 
 
3.1 Cell Preparation 
3.1.1 Cell Line and Growth 
B16-F10 mouse melanoma cells (ATCC #:  CRL-6475) were obtained and grown 
in McCoy’s Media (Cellgro Mediatech, Inc., Herndon, VA), adjusted to contain 10% 
fetal bovine serum (Cellgro Mediatech, Inc.) and (25mg) gentamicin 50mg/mL 
(Mediatech, Inc.), and were incubated in 5% CO2 at 37°C.  Serum was essential for many 
reasons.  It provided hormonal factors that stimulated cell growth and function.  It also 
contains essential proteins, amino acids, minerals, and lipids [35].  Gentamicin is an 
antibiotic used as a preventative measure to help reduce microbial growth and 
contamination.  
 
Figure 3.1  Untreated B16-F10 Cells in McCoy’s Media (100X) (Left) and in PBS (200X) (Right)    
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B16F10 cells grow exponentially as adherent monolayers (Figure 3.1), and 
required fluid renewal and/or sub-culturing every 2 to 3 days using 0.25% trypsin-EDTA 
(Sigma Chemical Co., St. Louis, MO) for detachment.   
 
3.1.2 Counting 
After harvesting, the cells were washed 3 times by centrifugation.  Cells were 
centrifuged (5810R, Eppendorf, Westbury, NY) at 220 × g for 5 minutes at 37°C and 
resuspended in approximately 2.5 ml of PBS for each wash.  A sample of cells was then 
diluted in 0.9% sodium chloride (APP, Schaumburg, IL) and 0.4% trypan blue stain 
(Cellgro Mediatech, Inc.).  Trypan blue is an indicator in which the membranes of non-
viable cells are penetrated and can be distinguished from the viable cells.  Using a 
hemacytometer (Hausser Scientific, Horsham, PA), the viable and nonviable cells were 
counted.  The number of cells per milliliter was computed by multiplying the number of 
cells counted per square millimeter × the dilution (when used) × 10,000 (conversion 
factor).  Only those cultures that resulted in 80% to 100% viability were used for 
experimentation.   
 
3.1.3 Well Seeding 
Experiments in this study were conducted using 48-well tissue culture plates (BD 
Falcon, Franklin Lakes, NJ) made from polystyrene.  Each well held approximately 1.4 
ml of liquid with a surface area of 0.75 cm2.  The depth and diameter of each well were 
18 mm and 10 mm, respectively. 
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From experimentation, it was found that pre-treatment of the wells with a 0.1% 
gelatin (Acros, NJ, USA; Geel, Belgium) film coat reduced loosening of the cells after 
electrical stimulation.  Under aseptic conditions, 150µl of the sterile gelatin solution was 
added to each well and let stand for 1 hour.  The gelatin was then aspirated from each of 
the wells and air dried for 5 minutes.  500µl of McCoy’s Media was added to the treated 
wells in addition to 7.5 ×104 viable cells and incubated at 37°C for 18 hours before 
treatment. 
 
3.2 Electrode  
Gilbert et al [36] designed and compared several innovative electrodes for use in 
electrochemotherapy treatment of murine B16 melanoma tumors.  They found that a 6-
needle array was the most successful when tested in vivo, measured statistically by a 
97.1% complete response rate. 
                
Figure 3.2  6-Prong Electrode Design 
 
The electrode shown in Figure 3.2 was specially designed for all experimentation 
in this thesis and was similar to the design mentioned above.  The electrode consisted of 
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6 stainless steel electrodes, equally spaced at 60° intervals around a 0.7 cm diameter 
circle.  The needles extended 1.8 cm from the electrode body to fit precisely in the wells 
in order to set flush against the treatment/cell growth surface.   
Cells in each well were treated with a total of 12 DC pulses.  Figure 3.3 illustrates 
the sequence pattern used to energize specific needles, where each small circle represents 
the location of each needle.  Pulses were directed to each needle by a rotary switch.  
Needles 1 & 2 were negative (represented as dark circles) for the first two consecutive 
pulses, whereas opposing needles 4 & 5 (represented as lightly shaded circles) were 
positive.  This pattern was repeated for the next two pulses except the pattern was rotated 
one-needle clockwise.  This clockwise rotation preceded each set of two pulses and was 
repeated until 12 pulses were delivered.  This sequence was designed to treat 360° of the 
cell growth surface.   
 
Figure 3.3  6-Needle Pulsing Sequence Used for Energizing Cells [36] 
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3.3    Testing Conditions & Experimental Protocol 
A hot water bath (Isotemp 105, Fisher Scientific, Hampton, NH) was used during 
the treatment of the cultures to maintain cell viability and was set at 50°C.  A sheet of 
Plexiglas was cut to fit over the water bath and was used as a surface for maintaining an 
approximate temperature of 37°C.  All solutions used were allowed to reach room 
temperature (~22°C) to prevent thermal shock to the cells. 
The absolute amplitude for the DC pulse generator (Transfector 800; BTX, Inc., 
San Diego, CA) ranged from 0-970 V, which corresponds to electric field intensities 
delivered between 0-1385 V/cm.  The pulse width was set within optimal conditions at 99 
µsec (maximum).  Using short electrical pulses for cellular manipulation has the 
advantage of resulting in negligible thermal heating [12].    
Each set of treatment conditions was tested in triplicate wells.  18 hours after 
seeding plates, each well was treated individually by aspirating the media, and quickly 
adding 150 µl of solution, just enough to coat the bottom of the well.  For those 
conditions that required electric current, the electrode was placed down in the well so that 
the prongs set flush on the bottom to minimize any movement of the electrode (Figure 
3.4).  Electrical current was then applied in the manner that was described in Section 3.2.   
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Figure 3.4   Demonstration of Electrical Treatment 
After application of the pulses, cells were incubated for 1 hour at 37°C.  This time 
allowed membrane resealing before the cells were carefully washed with 500 µl aliquots 
of PBS three times.  Liquid from each wash was carefully and thoroughly aspirated.  
Then, each well was filled with 500 µl of PBS.    
The presence of delivered calcein was observed under the microscope with the aid 
of a fluorescence microscope.  A 0.9% sodium dodecyl sulfate (SDS) solution was then 
used to lyse the cells after the completion of the washing.  SDS is a detergent that 
dissolves hydrophobic molecules, therefore when cells are incubated with an SDS 
solution, the membrane proteins and lipids denature and solubilize.  250 µl of the SDS 
solution was added to each of the wells containing PBS to yield a final concentration of 
0.3%.   
The contents of each well were transferred to a 5 ml FACS tube (BD Falcon).  An 
additional 500 µl of PBS was added to each tube to increase sample volume.  All samples 
were then centrifuged at 220 × g for 5 minutes at 37°C.   
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3.4  Fluorescence Measurements 
Individual readings of each sample were taken using a fluorescence spectrometer 
(Perkin-Elmer LS-3B, Oakbrook, IL).  The optimal excitation and emission wavelengths 
for calcein were found to be 488 and 515, respectively.  The readings were made in a 1 
cm2 quartz cuvette, using a sample volume of 1 ml.   
 
3.5   Membrane Recovery 
The membrane integrity of the cells after electroporation treatment is an essential 
factor in determining the applications in which this procedure will be utilized.  It is 
typically desired to preserve, as much as possible, the original cellular structures of these 
living membranes in order to obtain optimal post-treatment results.  As mentioned earlier, 
cellular membranes can undergo REB in which the biological structures will eventually 
return to their normal state.  Twenty four hours post-treatment, the fate of the cells can 
typically be determined.  For the purpose of this study, optimal testing conditions were 
used to treat B16F10 cells to conclude the extent of reversible permeation.        
Due to the large surface area of the wells, the cells were physically counted by 
observing 7 out of 21 fields of view along the horizontal diameter of each well at a 
magnification of 400× (see Figure 3.6).  The recovery of the membranes after exposure to 
each treating condition was expressed as a percentage of live cells remaining after each 
hour. 
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Figure 3.5  Fields of View for One Well at 400× Magnification.  The shaded circles represent the fields of 
view selected for counting 
 
In order to distinguish the viable cells from the dead, a 0.4% trypan blue solution 
in PBS was used.  150µl of the solution was added to each well for 1 minute, and then the 
cells were counted using the described method.  Each test condition was studied at 1 hour 
intervals ranging from 1 hour to 4 hours.  In addition, membrane recovery was examined 
24 hours post treatment. 
 
3.6 B16F10 Cell Size Measurements 
  The size and shape of the cells may alter when exposed to solutions that will 
penetrate the membranes during electroporation.  Therefore some samples in this study 
were further investigated in order to determine the extent of change that occurred due to 
membrane swelling.  Due to the variety of shapes the cells can take under the conditions 
of E.P., sizes of two axis were collected from cells for each treatment condition, the long 
axis (horizontal) and short axis (vertical).  A stage micrometer was used to calibrate the 
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reticle in the eyepiece of the microscope to a standardized measurement scale at each 
magnification under a white light, where each unit on the reticle is configured to measure 
in micrometers.  
 
3.7  pH Measurements 
 The three concentrations of ASA, SA, and AA had pH values that were 
determined.  The pH measurements were made using a pH meter (Colloidal Dynamics, 
AZR2, Sydney, Australia), which was calibrated using 3 solutions with known pH values.  
The pH values of each solution were 4, 7, and 10.   
             
3.8  Statistical Methods  
To determine the statistical relevance of the data, a criterion for considering the 
mean data of one treatment condition as more successful than another had to be 
established.  The null hypothesis used was that no change took place when considering 
one set of treatment parameters over another, and the alternative hypothesis used was that 
a significant change took place that resulted in different mean fluorescence values.  The 
method used to test the null hypothesis was a two-tailed paired sample t test, with a level 
of significance of α = 0.05.  If the computed t-score was in between the critical values, 
then the null hypothesis would be accepted, whereas if the t-score was a value that lied 
outside of the critical value parameters, there would be significant evidence to allow for a 
conclusion that the treatments differed in their effectiveness. 
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CHAPTER 4:  RESULTS & CONCLUSIONS 
 
4.1   Effects of Salicylic Acid on Calcein Delivered by E.P. 
The first set of experiments conducted in this investigation focused on the effects 
of salicylic acid on the delivery of calcein to B16F10 cells using electroporation.  Three 
identical experiments were carried out.  Figure 4.1 shows mean spectrofluorometric data 
for these experiments.  All cells were exposed to 120 µM calcein.  In addition, cells in 
some samples were exposed to one of three different concentrations of SA (1 mM, 5 mM, 
or 10 mM) with pH values of 6.70, 6.32, and 3.85, respectively.  Pulses with one of four 
different field strengths were also applied (500, 750, 1000, or 1385 V/cm) to certain 
samples.  SA concentration and field strength were experimental variables; however, 
some cells were not exposed to applied fields or SA for comparison/control purposes.    
The results demonstrated that when cells were exposed to calcein and the three 
concentrations of SA (no applied electric field), SA did not augment the delivery when 
compared to samples exposed to calcein alone.  Overall, the data for samples treated with 
calcein and either 1, 5, or 10 mM SA and electrical pulses were not significantly higher in 
fluorescent magnitude than any of the samples that were treated with calcein and pulses 
(no SA).  Therefore, this suggests that SA is not a viable candidate for enhancing 
electroporative delivery of calcein.   
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Figure 4.1  Electroporated Delivery with Salicylic Acid:  Mean and S.E.M. of 3 Experiments 
 
4.2  Effects of Acetylsalicylic Acid on Calcein Delivered by E.P. 
The second set of experiments conducted in this investigation focused on the 
delivery of calcein using aspirin.  The treatments were similar to those in section 4.1 in 
that three concentrations of aspirin were used (1 mM, 5 mM, or 10 mM) with pH values 
of 6.39, 5.40, and 4.40, respectively.  The same range of pulsing conditions was used and 
the variables were identical for the sample treatment.  Figure 4.2 shows the mean data 
from three replicate experiments.  The data indicates that exposure to 1 mM, or 5 mM 
ASA (alone) did not result in a significant increase in fluorescence magnitude when 
compared to the treatment of 120 µM calcein alone (no ASA).  In addition, samples 
treated with 1 and 5 mM ASA that were also exposed to electric fields had mean 
fluorescence magnitude that were not significantly different from those samples that were 
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exposed to electric fields alone (no ASA).  In contrast, samples that were exposed to 
calcein in 10mM ASA (no pulses) had an average fluorescent magnitude of 4.28 (SEM = 
0.63) and samples that were exposed to calcein (no ASA or pulses) had mean fluorescent 
magnitude 0.83 (SEM = 0.05).  This 5-fold increase in internalized calcein that resulted 
from exposure to 10mM ASA was statistically significant when compared to the control 
sample (p < 0.0001).  Figure 4.2 also demonstrates that 10 mM ASA assisted in the 
delivery of calcein at each of the four electric fields.  As the applied field was increased, 
the fluorescence remained at an elevated magnitude relative to samples that were exposed 
to 10mM ASA (alone) and to samples that were exposed to same electric fields alone.  At 
500 V/cm (and 10mM ASA), there was a 3.7-fold increase in fluorescence magnitude 
relative to samples treated with calcein at 500 V/cm (no ASA).  These same increases at 
750, 1000, and 1385 V/cm were 3.82, 3.57, and 3.18-fold, respectively.  The mean data 
with samples treated at each field were significantly different from analogous samples 
that did not include ASA.  The p-values of these comparisons were < 0.0001 (500 V/cm), 
0.0011 (750 V/cm), 0.0014 (1000 V/cm), and 0.0066 (1385 V/cm). Therefore, these data 
clearly show that 10 mM ASA alone can augment calcein delivery alone to the exterior of 
cells and also enhance delivery as a result of electroporation. 
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Figure 4.2  Electroporated Delivery with Acetylsalicylic Acid:  Mean and S.E.M of 3 Experiments 
 
4.3   Effects of Acetic Acid on Calcein Delivered by E.P. 
The third set of experiments included the investigation of calcein delivery by E.P. 
using acetic acid as an adjuvant.  The set of 3 replicate experiments included three 
concentrations of AA, each with a different pH (4.40, 5.36, or 6.42).  The pH values of 
the three solutions of acetic acid were matched to those of ASA for the purpose of 
determining if AA is the derivative in ASA that enhances the delivery of calcein.  The 
three concentrations of the AA solutions in PBS were similar, which was about 0.15%, 
and varied slightly in order to establish the desired pH value.  In addition, one of three 
electric field strengths were applied to cells (500, 750, or 1000 V/cm).  Some cells were 
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not exposed to applied fields or any concentration of AA for purposes of comparison and 
control.    
Samples treated with acetic acid failed to show a significant increase in 
fluorescence magnitude at higher pH (5.36 or 6.42) regardless of whether or not pulses 
were applied, when compared to samples not exposed to AA.  However, Figure 4.3 
shows that acetic acid had a tremendous effect on the delivery of calcein, using a low pH 
solution (pH 4.40).  The data for samples treated with AA alone (no pulses with a mean 
fluorescence magnitude of 1.04) was significantly different in mean fluorescence when 
compared to control samples that were not treated with AA or pulses (mean fluorescence 
magnitude of 8.57).  This was an 8.2-fold increase.  When electric fields were used in 
combination with the lowest pH solution of AA, fluorescent data was even higher than 
when this concentration of AA was used alone (no pulses).   
The data for samples treated with AA and electrical pulses was significantly 
higher than any of the samples that were treated with calcein and pulses (no AA).  At the 
lowest applied field, 500 V/cm, acetic acid augmented the resulting fluorescence 
magnitude by 3-fold.  The mean fluorescence magnitudes were 12.77 for samples treated 
with AA (pH 4.40) and 4.19 for the samples that were not exposed to AA.  This 
difference was significant (p < 0.0001).  For the 750 V/cm samples, this same increase 
was 2.25-fold and was statistically significant (p = 0.0002).  Similarily, there was a 3.5-
fold increase for the 1000 V/cm samples.  This increase was also significant (p < 0.0001).   
As a result of this data, a low pH (4.40) solution of acetic acid is clearly a 
candidate to augment calcein for optimal E.P. delivery of calcein in B16F10 cells at any 
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of the three electric fields, though it is often desired to apply lower field strengths to 
minimize the possibility of cellular damage.   
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Figure 4.3  Electroporated Delivery with Acetic Acid:  Mean and S.E.M of 3 Experiments 
 
4.4 Membrane Recovery 
Acetic acid was chosen as the optimal for this study, therefore, further 
investigation of the effects it had on cell membranes was carried out.  An ideal method of 
delivery would result in cell membranes that are intact after the method was performed. 
The trypan blue test was used to determine membrane integrity as trypan blue dye will 
only penetrate into cells that have porous membranes.  The electric field strength of 750 
V/cm was applied to triplicate wells containing PBS alone as well as acetic acid 
(pH.4.40) alone.  In addition, for comparison, individual treatments of PBS and acetic 
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acid (pH 4.40) without electrical pulses were investigated.  The protocol used was similar 
to the methods described for the delivery of calcein, after one hour of exposure at 37°, the 
cells were washed three times with 500 µl aliquots of PBS.  Liquid from the last wash 
was carefully aspirated, and then filled with 500 µl of growth media. 
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Figure 4.4  Membrane Recovery of Cells after Exposure:  Mean and S.D. of 3 Experiments 
 
 
Figure 4.4 illustrates the time duration of membrane recovery after exposure.  
Treatments with PBS alone (no pulses) and with 750 V/cm applied electric field yielded 
between 90-100% membrane recovery during the 24 hours of observation.  However, 
acetic acid alone had a greater impact on the recovery of the cells, ranging from an 
average of 80-95% membrane integrity.  At a time of 1 hour post-treatment for samples 
treated with acetic acid at 750 V/cm, there was a 17% decline in the number of cells with 
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intact membranes, implying that some of the cells either did not survive after exposure or 
was permeabilized.  The number of cells that excluded the trypan blue dye then increased 
as the hours proceeded to a value of 86% after 24 hours.  90% of the cells exposed to AA 
alone had intact membranes 24 hours after treatment.  
 
4.5  B16F10 Cell Sizes Post Treatment 
After the cells had been exposed to any of the treatment conditions mentioned 
earlier, they varied slightly in shape and size due to membrane swelling as determined by 
direct observation.  This phenomenon is an indication that fluid was being delivered 
through the cell’s membrane.  An investigation as to how much more swelling occurred 
at various conditions, compared to normal B16F10 cells, was conducted.  Due to the 
nature of the shape and size changes, both horizontal (long axis) and vertical (short axis) 
dimensions were collected for 30 cells for each treatment condition at a magnification of 
400×.  The treatment conditions investigated consisted of PBS (no pulses), 10mM ASA 
(no pulses), 10mM ASA and pulses at 750 V/cm, 10mM SA (no pulses), 10mM SA and 
pulses at 750 V/cm, AA (pH 4.40) (no pulses), and AA (pH 4.40) and pulses at 750 
V/cm.  For comparison and control purposes, measurements of 30 untreated cells were 
taken.   
The vertical axis of the untreated cells averaged 15µm, whereas the horizontal 
axis averaged 44.1µm.  The samples of cells investigated at any of the other treatment 
conditions were exposed to the solutions and pulses (when applied) between 
approximately 1-10 minutes before the measurements were taken.  Figure 3.5 shows the 
mean results of the measurements as well as the corresponding standard deviations.  It 
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can clearly be seen that there is no significant difference in the measured dimensions at 
any condition, compared to the untreated cells, and is confirmed using the two-tailed 
paired sample t test at the 0.05 significance level.   
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Figure 4.5  Vertical and Horizontal Axis of B16F10 Cells 
 
4.6 Conclusions and Discussion 
Aspirin and two of its derivatives were tested in this study, salicylic acid and 
acetic acid.  Two of the three succeeded in delivering calcein to cells.  ASA (10mM) and 
AA (pH 4.40) augmented the delivery of calcein at all 4 chosen electrical field strengths, 
but AA (pH4.40) was clearly a better candidate.  The low pH solution of AA alone (no 
pulses) augmented delivery, indicating a strong effect on the membranes, and improved 
with the presence of pulses.  When compared to any other treatment condition, including 
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those using ASA and SA, with or without the presence of electrical pulses, AA (pH 4.40) 
clearly resulted in higher mean fluorescence data.  Surprisingly, SA did not show a great 
effect in calcein delivery, given by the significance of statistical t tests.   
The fact that ASA and AA augmented delivery to the cells over SA may not be a 
coincidence.  As mentioned earlier, ASA will hydrolyze to AA and SA derivatives.  This 
is why acetic acid, in addition to SA, was chosen to be investigated.  After ASA showed 
to be successful in experimentation, it had to be established whether or not the presence 
of AA was the reason of such a promising result.     
A comparison of the data can help establish if pH alone is a determining factor of 
calcein delivery.  As an outcome, acetic acid (pH 4.40) resulted in higher mean 
spectrofluorometric data than that of ASA and/or SA at all treatment conditions.  The 
0.15% concentration of AA (pH 4.40) had a higher pH value than 10 mM SA (pH 3.86), 
and was equal to the pH of 10 mM ASA (pH 4.40).  This indicates that the successful 
delivery of calcein was not the direct effect of a low pH solution, and that 0.15% acetic 
acid with a pH of 4.40 inherently is the most optimal in delivering calcein to B16F10 
cells by electroporation.  
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Appendix A:  Data Collected for Salicylic Acid Trials 
 
Table A.1  Salicylic Acid Delivery:  Experiment 1 
Treatment 1 2 3 Average Standard Deviation
Control 0.4 0.1 0.1 0.20 0.17
CALCEIN 1.2 2.2 0.6 1.33 0.81
1mM SA&CAL 0.6 0.6 1.3 0.83 0.40
5mM SA&CAL 0.5 0.5 0.9 0.63 0.23
10mM SA&CAL 3.2 2.4 2.1 2.57 0.57
CALCEIN 0.8 1.8 1 1.20 0.53
1mM SA&CAL 3.2 1.5 1.5 2.07 0.98
5mM SA&CAL 2.8 8.8 4.3 5.30 3.12
10mM SA&CAL 5.4 7 5.3 5.90 0.95
CALCEIN 4.5 3.4 5.2 4.37 0.91
1mM SA&CAL 1.7 2.3 4 2.67 1.19
5mM SA&CAL 1.6 2.6 15.9 6.70 7.98
10mM SA&CAL 0.9 1.2 2.3 1.47 0.74
CALCEIN 3 3.9 4.4 3.77 0.71
1mM SA&CAL 2.9 3.5 8.2 4.87 2.90
5mM SA&CAL 2.5 1.5 1.2 1.73 0.68
10mM SA&CAL 3.3 1.7 1.1 2.03 1.14
CALCEIN 4.6 3.2 3 3.60 0.87
1mM SA&CAL 4 4.1 3.4 3.83 0.38
5mM SA&CAL 3.1 3.1 4.4 3.53 0.75
10mM SA&CAL 2.9 1 3.8 2.57 1.431
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Appendix A: (Continued) 
 
Table A.2  Salicylic Acid Delivery:  Experiment 2 
Treatment 1 2 3 Average Standard Deviation
Control 0.2 0.1 0.1 0.13 0.06
CALCEIN 2.3 1.1 2.7 2.03 0.83
1mM SA&CAL 1.1 0.6 1.4 1.03 0.40
5mM SA&CAL 1.5 2.7 2.2 2.13 0.60
10mM SA&CAL 0.9 1 1 0.97 0.06
CALCEIN 2.9 2.2 1.3 2.13 0.80
1mM SA&CAL 2.9 3.1 2.6 2.87 0.25
5mM SA&CAL 3.1 2.7 2.1 2.63 0.50
10mM SA&CAL 4.3 2.4 6.1 4.27 1.85
CALCEIN 1.9 1.7 2.9 2.17 0.64
1mM SA&CAL 1.9 3.5 3.8 3.07 1.02
5mM SA&CAL 1.8 1.1 2.5 1.80 0.70
10mM SA&CAL 3.3 4.2 2.4 3.30 0.90
CALCEIN 2.4 2.2 2.3 2.30 0.10
1mM SA&CAL 3 2.5 3.7 3.07 0.60
5mM SA&CAL 1.3 3.8 3.2 2.77 1.31
10mM SA&CAL 1.6 2.4 2.6 2.20 0.53
CALCEIN 3.5 1.2 2.2 2.30 1.15
1mM SA&CAL 1.8 1.7 1.9 1.80 0.10
5mM SA&CAL 2.5 1.3 1.6 1.80 0.62
10mM SA&CAL 1.6 1.6 0.6 1.27 0.58
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Appendix A:  (Continued) 
 
Table A.3  Salicylic Acid Delivery:  Experiment 3 
Treatment 1 2 3 Average Standard Deviation
Control 0.3 0.5 0.5 0.43 0.12
CALCEIN 1.1 0.6 0.8 0.83 0.25
1mM SA&CAL 0.6 1.8 0.9 1.10 0.62
5mM SA&CAL 1.4 0.9 0.7 1.00 0.36
10mM SA&CAL 0.7 0.5 1 0.73 0.25
CALCEIN 6.3 4.6 3.9 4.93 1.23
1mM SA&CAL 1.2 2.9 3.3 2.47 1.12
5mM SA&CAL 2.5 4 0.9 2.47 1.55
10mM SA&CAL 3.5 2.4 2.4 2.77 0.64
CALCEIN 2.6 2.5 3.1 2.73 0.32
1mM SA&CAL 2.4 2.8 1.9 2.37 0.45
5mM SA&CAL 4.4 1.8 2.3 2.83 1.38
10mM SA&CAL 3.1 2.4 2.6 2.70 0.36
CALCEIN 3.8 5.2 2.8 3.93 1.21
1mM SA&CAL 3.2 2 2.9 2.70 0.62
5mM SA&CAL 2.8 2.8 2.6 2.73 0.12
10mM SA&CAL 1.9 1.9 2.4 2.07 0.29
CALCEIN 2.9 2.8 2.8 2.83 0.06
1mM SA&CAL 2.9 2.6 2.3 2.60 0.30
5mM SA&CAL 0.8 1.9 1.9 1.53 0.64
10mM SA&CAL 7.1 2.2 3.9 4.40 2.49
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Appendix A:  (Continued) 
 
Table A.4  Salicylic Acid Delivery:  Average of 3 Experiments 
 
Treatment Average Standard Deviation
Standard 
Error Mean
Control, PBS 0.26 0.17 0.10
CALCEIN 1.40 0.79 0.46
1mM SA&CAL 0.99 0.44 0.25
5mM SA&CAL 1.26 0.77 0.45
10mM SA&CAL 1.42 0.92 0.53
CALCEIN 2.76 1.86 1.07
1mM SA&CAL 2.47 0.83 0.48
5mM SA&CAL 3.47 2.24 1.29
10mM SA&CAL 4.31 1.74 1.00
CALCEIN 3.09 1.15 0.66
1mM SA&CAL 2.70 0.87 0.50
5mM SA&CAL 3.78 4.64 2.68
10mM SA&CAL 2.49 1.01 0.58
CALCEIN 3.33 1.05 0.60
1mM SA&CAL 3.54 1.82 1.05
5mM SA&CAL 2.41 0.90 0.52
10mM SA&CAL 2.10 0.65 0.37
CALCEIN 2.91 0.92 0.53
1mM SA&CAL 2.74 0.92 0.53
5mM SA&CAL 2.29 1.11 0.64
10mM SA&CAL 2.74 2.00 1.151
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Appendix B:  Data Collected for Acetylsalicylic Acid Experiments 
 
Table B.1  Acetylsalicylic Acid Delivery:  Experiment 1 
Treatment 1 2 3 Average Standard Deviation
Control, PBS 0.4 0 0 0.13 0.23
CALCEIN 0.3 0.7 0.5 0.50 0.20
1mM ASA&CAL 0.5 0.6 0.8 0.63 0.15
5mM ASA&CAL 0.7 28.5 1.4 10.20 15.85
10mM ASA&CAL 3.9 5.2 6.4 5.17 1.25
CALCEIN 1.9 1.2 1.4 1.50 0.36
1mM ASA&CAL 2.3 2.7 2.8 2.60 0.26
5mM ASA&CAL 2.3 4.4 4.1 3.60 1.14
10mM ASA&CAL 9.9 12.7 13.9 12.17 2.05
CALCEIN 3.2 3.3 3.5 3.33 0.15
1mM ASA&CAL 3.7 2.8 3.4 3.30 0.46
5mM ASA&CAL 1.8 3.3 4.1 3.07 1.17
10mM ASA&CAL 13.8 15.1 20.9 16.60 3.78
CALCEIN 6.1 2.4 1.9 3.47 2.29
1mM ASA&CAL 3.2 4.1 4.5 3.93 0.67
5mM ASA&CAL 5.8 3.8 5.8 5.13 1.15
10mM ASA&CAL 19.4 11.6 16.9 15.97 3.98
CALCEIN 4 4.1 3.8 3.97 0.15
1mM ASA&CAL 3.5 3.9 3.9 3.77 0.23
5mM ASA&CAL 8.1 3.5 5.6 5.73 2.30
10mM ASA&CAL 16.1 17.6 18.5 17.40 1.21
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Appendix B:  (Continued) 
 
Table B.2  Acetylsalicylic Acid Delivery:  Experiment 2 
Treatment 1 2 3 Average Standard Deviation
Control, PBS 0.3 0.3 0.2 0.27 0.06
CALCEIN 0.7 1.3 0.6 0.87 0.38
1mM ASA&CAL 0.8 1.8 0.5 1.03 0.68
5mM ASA&CAL 1.8 1.1 0.8 1.23 0.51
10mM ASA&CAL 2.7 2.5 4 3.07 0.81
CALCEIN 2.7 1.3 2.8 2.27 0.84
1mM ASA&CAL 3.1 2.9 3 3.00 0.10
5mM ASA&CAL 1.9 1.8 3.6 2.43 1.01
10mM ASA&CAL 4.6 7.2 7 6.27 1.45
CALCEIN 2.4 3.2 2.5 2.70 0.44
1mM ASA&CAL 1.6 3.4 4.5 3.17 1.46
5mM ASA&CAL 5.1 4.3 2.5 3.97 1.33
10mM ASA&CAL 11.1 7.2 8.3 8.87 2.01
CALCEIN 1.9 3.5 2.3 2.57 0.83
1mM ASA&CAL 2.4 3 3.5 2.97 0.55
5mM ASA&CAL 2.2 2.8 3.7 2.90 0.75
10mM ASA&CAL 11.4 10.8 9.8 10.67 0.81
CALCEIN 1.9 2.4 4.2 2.83 1.21
1mM ASA&CAL 3.1 7.1 2.4 4.20 2.54
5mM ASA&CAL 2.5 3.1 4 3.20 0.75
10mM ASA&CAL 12.1 6.1 10.2 9.47 3.07
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Appendix B:  (Continued) 
 
Table B.3  Acetylsalicylic Acid Delivery:  Experiment 3 
Treatment 1 2 3 Average Standard Deviation
Control, PBS 0.1 0.3 0.1 0.17 0.12
CALCEIN 0.4 0.6 0.6 0.53 0.12
1mM ASA&CAL 1.3 0.5 1.7 1.17 0.61
5mM ASA&CAL 0.6 1 0.9 0.83 0.21
10mM ASA&CAL 2.5 4.3 7 4.60 2.26
CALCEIN 5.6 2 1.3 2.97 2.31
1mM ASA&CAL 1.1 2 2 1.70 0.52
5mM ASA&CAL 4.5 2.8 3.2 3.50 0.89
10mM ASA&CAL 6.1 7.9 6.2 6.73 1.01
CALCEIN 2.4 1.9 2.4 2.23 0.29
1mM ASA&CAL 2.2 3.4 1.5 2.37 0.96
5mM ASA&CAL 2.6 3.7 2.5 2.93 0.67
10mM ASA&CAL 4.8 4.2 9.9 6.30 3.13
CALCEIN 3.2 2.8 2.1 2.70 0.56
1mM ASA&CAL 4.5 3.1 2.5 3.37 1.03
5mM ASA&CAL 4.5 3.9 4.2 4.20 0.30
10mM ASA&CAL 4 4.3 5.3 4.53 0.68
CALCEIN 3 2.5 2.4 2.63 0.32
1mM ASA&CAL 2.5 2.6 3.2 2.77 0.38
5mM ASA&CAL 4.4 3.4 7.6 5.13 2.19
10mM ASA&CAL 3.4 1.2 4.7 3.10 1.77
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Appendix B:  (Continued) 
 
Table B.4  Acetylsalicylic Acid Delivery:  Average of 3 Experiments 
 
Treatment Average Standard Deviation
Standard 
Error Mean
Control, PBS 0.19 0.07 0.04
CALCEIN 0.63 0.20 0.12
1mM ASA&CAL 0.94 0.28 0.16
5mM ASA&CAL 4.09 5.30 3.06
10mM ASA&CAL 4.28 1.09 0.63
CALCEIN 2.24 0.73 0.42
1mM ASA&CAL 2.43 0.67 0.38
5mM ASA&CAL 3.18 0.65 0.37
10mM ASA&CAL 8.39 3.28 1.89
CALCEIN 2.76 0.55 0.32
1mM ASA&CAL 2.94 0.50 0.29
5mM ASA&CAL 3.32 0.56 0.32
10mM ASA&CAL 10.59 5.36 3.10
CALCEIN 2.91 0.49 0.28
1mM ASA&CAL 3.42 0.49 0.28
5mM ASA&CAL 4.08 1.12 0.65
10mM ASA&CAL 10.39 5.72 3.30
CALCEIN 3.14 0.72 0.42
1mM ASA&CAL 3.58 0.74 0.42
5mM ASA&CAL 4.69 1.32 0.76
10mM ASA&CAL 9.99 7.16 4.141
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Appendix C:  Data Collected for Acetic Acid Experiments 
 
Table C.1  Acetic Acid Delivery:  Experiment 1 
Treatment 1 2 3 Average Standard Deviation
Control 0.2 0.1 0.2 0.17 0.06
CALCEIN 1.1 1.6 1.4 1.37 0.25
Acetic Acid pH 6.42 3.3 2.4 4.7 3.47 1.16
Acetic Acid pH 5.36 4.8 4.7 2.4 3.97 1.36
Acetic Acid pH 4.40 7.5 10 8.1 8.53 1.31
CALCEIN 4.9 4 4.5 4.47 0.45
Acetic Acid pH 6.42 3.5 4.7 4.8 4.33 0.72
Acetic Acid pH 5.36 4.7 3.5 4 4.07 0.60
Acetic Acid pH 4.40 12.1 13.1 10.8 12.00 1.15
CALCEIN 4.7 2.3 2.8 3.27 1.27
Acetic Acid pH 6.42 3.5 4.1 4.7 4.10 0.60
Acetic Acid pH 5.36 5.7 3.8 4.7 4.73 0.95
Acetic Acid pH 4.40 18.3 17.4 12.8 16.17 2.95
CALCEIN 6.1 4.7 4.9 5.23 0.76
Acetic Acid pH 6.42 4.2 9.8 5.5 6.50 2.93
Acetic Acid pH 5.36 5.6 5.5 4.4 5.17 0.67
Acetic Acid pH 4.40 17.5 17 21.3 18.60 2.35
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Appendix C:  (Continued) 
 
Table C.2  Acetic Acid Delivery:  Experiment 2 
Treatment 1 2 3 Average Standard Deviation
Control 0.4 0.2 0.2 0.27 0.12
CALCEIN 0.8 1 0.8 0.87 0.12
Acetic Acid pH 6.42 0.8 1.2 1.2 1.07 0.23
Acetic Acid pH 5.36 1.5 3.5 2.2 2.40 1.01
Acetic Acid pH 4.40 8.4 8.8 11.1 9.43 1.46
CALCEIN 4.6 3.1 2.7 3.47 1.00
Acetic Acid pH 6.42 2 4.9 5.1 4.00 1.73
Acetic Acid pH 5.36 4.9 4.8 5.3 5.00 0.26
Acetic Acid pH 4.40 12.9 13.7 12.6 13.07 0.57
CALCEIN 7.4 9.5 7.8 8.23 1.12
Acetic Acid pH 6.42 5.2 3.8 5.7 4.90 0.98
Acetic Acid pH 5.36 6.8 5.9 5.4 6.03 0.71
Acetic Acid pH 4.40 9.7 8.5 11 9.73 1.25
CALCEIN 4.8 4.4 2.6 3.93 1.17
Acetic Acid pH 6.42 3.6 2 2.4 2.67 0.83
Acetic Acid pH 5.36 3.5 0.7 3.4 2.53 1.59
Acetic Acid pH 4.40 21.1 20.7 20.3 20.70 0.40
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Appendix C:  (Continued) 
 
Table C.3  Acetic Acid Delivery:  Experiment 3 
Treatment 1 2 3 Average Standard Deviation
Control 0.3 0.5 0.5 0.43 0.12
CALCEIN 1.1 0.7 0.9 0.90 0.20
Acetic Acid pH 6.42 1.5 1.6 1.4 1.50 0.10
Acetic Acid pH 5.36 0.8 1.2 0.8 0.93 0.23
Acetic Acid pH 4.40 6.2 8 9 7.73 1.42
CALCEIN 5.6 3.3 5 4.63 1.19
Acetic Acid pH 6.42 2.9 4 4.5 3.80 0.82
Acetic Acid pH 5.36 2.4 3.6 6 4.00 1.83
Acetic Acid pH 4.40 10.6 16.1 13 13.23 2.76
CALCEIN 4.4 4.8 4.8 4.67 0.23
Acetic Acid pH 6.42 5.2 3.6 7.9 5.57 2.17
Acetic Acid pH 5.36 5.3 2.6 2.3 3.40 1.65
Acetic Acid pH 4.40 8.7 10.9 11.9 10.50 1.64
CALCEIN 6 6 3.2 5.07 1.62
Acetic Acid pH 6.42 3.5 3 1.9 2.80 0.82
Acetic Acid pH 5.36 3.6 3.2 4.3 3.70 0.56
Acetic Acid pH 4.40 10.5 9.4 10.5 10.13 0.641
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Appendix C:  (Continued) 
 
Table C.4  Acetic Acid Delivery:  Average of 3 Experiments 
 
Treatment Average Standard Deviation
Standard 
Error Mean
Control, PBS 0.29 0.15 0.08
CALCEIN 1.04 0.30 0.17
Acetic Acid pH 6.42 2.01 1.26 0.73
Acetic Acid pH 5.36 2.43 1.57 0.91
Acetic Acid pH 4.40 8.57 1.42 0.82
CALCEIN 4.19 0.98 0.56
Acetic Acid pH 6.42 4.04 1.05 0.61
Acetic Acid pH 5.36 4.36 1.09 0.63
Acetic Acid pH 4.40 12.77 1.63 0.94
CALCEIN 5.39 2.38 1.37
Acetic Acid pH 6.42 4.86 1.38 0.80
Acetic Acid pH 5.36 4.72 1.53 0.88
Acetic Acid pH 4.40 12.13 3.54 2.04
CALCEIN 4.74 1.23 0.71
Acetic Acid pH 6.42 3.99 2.46 1.42
Acetic Acid pH 5.36 3.80 1.46 0.84
Acetic Acid pH 4.40 16.48 5.00 2.891
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Appendix D:  Data Collected for Membrane Recovery 
 
Table D.1  Membrane Recovery after 1 Hour 
Live Dead Total Count % Dead % Viable SD
1 59 1 60 1.7 98.3
2 64 2 66 3.0 97.0
3 65 2 67 3.0 97.0
average 62.7 1.7 64.3 2.6 97.4 0.8
1 43 4 47 8.5 91.5
2 62 9 71 12.7 87.3
3 103 12 115 10.4 89.6
average 69.3 8.3 77.7 10.5 89.5 2.1
1 54 7 61 11.5 88.5
2 57 5 62 8.1 91.9
3 63 3 66 4.5 95.5
average 58.0 5.0 63.0 8.0 92.0 3.5
1 53 12 65 18.5 81.5
2 67 16 83 19.3 80.7
3 55 16 71 22.5 77.5
average 58.3 14.7 73.0 20.1 79.9 2.2
1 HOUR POST-EXPOSURE
PBS (no 
pulses)
AA (no 
pulses)
PBS, 750 
V/cm
AA, 750 
V/cm
 
 
Table D.2  Membrane Recovery after 2 Hours 
 
Live Dead Total Count % Dead % Viable SD
1 56 2 58 3.4 96.6
2 59 1 60 1.7 98.3
3 57 3 60 5.0 95.0
average 57.3 2.0 59.3 3.4 96.6 1.7
1 36 10 46 21.7 78.3
2 63 14 77 18.2 81.8
3 58 11 69 15.9 84.1
average 52.3 11.7 64.0 18.6 81.4 2.9
1 44 2 46 4.3 95.7
2 50 1 51 2.0 98.0
3 63 2 65 3.1 96.9
average 52.3 1.7 54.0 3.1 96.9 1.2
1 58 7 65 10.8 89.2
2 45 15 60 25.0 75.0
3 58 11 69 15.9 84.1
average 53.7 11.0 64.7 17.2 82.8 7.2
2 HOURS POST-EXPOSURE
PBS (no 
pulses)
AA (no 
pulses)
PBS, 750 
V/cm
AA, 750 
V/cm
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Appendix D:  (Continued) 
 
Table D.3  Membrane Recovery after 3 Hours 
Live Dead Total Count % Dead % Viable SD
1 51 4 55 7.3 92.7
2 54 5 59 8.5 91.5
3 47 3 50 6.0 94.0
average 50.7 4.0 54.7 7.2 92.8 1.2
1 95 5 100 5.0 95.0
2 64 10 74 13.5 86.5
3 45 12 57 21.1 78.9
average 68.0 9.0 77.0 13.2 86.8 8.0
1 56 2 58 3.4 96.6
2 55 2 57 3.5 96.5
3 37 5 42 11.9 88.1
average 49.3 3.0 52.3 6.3 93.7 4.9
1 57 2 59 3.4 96.6
2 74 9 83 10.8 89.2
3 66 5 71 7.0 93.0
average 65.7 5.3 71.0 7.1 92.9 3.7
3 HOURS POST-EXPOSURE
PBS (no 
pulses)
AA (no 
pulses)
PBS, 750 
V/cm
AA, 750 
V/cm
 
 
Table D.4  Membrane Recovery after 4 Hours 
Live Dead Total Count % Dead % Viable SD
1 64 4 68 5.9 94.1
2 59 2 61 3.3 96.7
3 55 2 57 3.5 96.5
average 59.3 2.7 62.0 4.2 95.8 1.4
1 45 3 48 6.3 93.8
2 72 6 78 7.7 92.3
3 49 4 53 7.5 92.5
average 55.3 4.3 59.7 7.2 92.8 0.8
1 58 3 61 4.9 95.1
2 47 1 48 2.1 97.9
3 56 3 59 5.1 94.9
average 53.7 2.3 56.0 4.0 96.0 1.7
1 55 4 59 6.8 93.2
2 57 4 61 6.6 93.4
3 73 6 79 7.6 92.4
average 61.7 4.7 66.3 7.0 93.0 0.5
4 HOURS POST-EXPOSURE
PBS (no 
pulses)
AA (no 
pulses)
PBS, 750 
V/cm
AA, 750 
V/cm
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Appendix D:  (Continued) 
 
Table D.5  Membrane Recovery after 24 Hours 
Live Dead Total Count % Dead % Viable SD
1 137 0 137 0.0 100.0
2 122 3 125 2.4 97.6
3 89 2 91 2.2 97.8
average 116.0 1.7 117.7 1.5 98.5 1.3
1 49 10 59 16.9 83.1
2 62 5 67 7.5 92.5
3 95 5 100 5.0 95.0
average 68.7 6.7 75.3 9.8 90.2 6.3
1 52 1 53 1.9 98.1
2 68 2 70 2.9 97.1
3 70 2 72 2.8 97.2
average 63.3 1.7 65.0 2.5 97.5 0.5
1 60 7 67 10.4 89.6
2 74 12 86 14.0 86.0
3 57 13 70 18.6 81.4
average 63.7 10.7 74.3 14.3 85.7 4.1
24 HOURS POST-EXPOSURE
PBS (no 
pulses)
AA (no 
pulses)
PBS, 750 
V/cm
AA, 750 
V/cm
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Appendix E:  B16F10 Cell Sizes Post Treatment 
 
Table E.1  B16F10 Cell Sizes 
V H V H V H V H V H V H V H V H
1 12.5 57.5 12.5 50 12.5 50 12.5 45 10 82.5 12.5 45 20 25 20 40
2 22.5 25 15 62.5 20 37.5 15 47.5 12.5 40 10 35 22.5 30 12.5 37.5
3 15 25 12.5 50 17.5 60 10 60 12.5 50 12.5 60 22.5 40 17.5 62.5
4 12.5 57.5 17.5 65 12.5 30 12.5 50 12.5 75 15 52.5 20 55 20 75
5 15 50 10 60 20 55 15 42.5 10 35 12.5 42.5 12.5 60 12.5 22.5
6 20 25 10 17.5 15 30 15 52.5 15 80 12.5 47.5 20 40 17.5 40
7 12.5 70 15 42.5 12.5 55 12.5 45 15 52.5 10 45 12.5 77.5 12.5 55
8 12.5 15 25 45 12.5 17.5 12.5 40 12.5 35 12.5 40 10 80 20 42.5
9 22.5 82.5 17.5 65 25 37.5 10 75 10 55 10 75 12.5 65 12.5 37.5
10 15 65 25 55 15 35 22.5 37.5 12.5 65 22.5 37.5 15 57.5 17.5 25
11 15 17.5 15 72.5 17.5 45 15 57.5 10 15 15 55 12.5 70 17.5 75
12 17.5 52.5 30 47.5 12.5 50 25 77.5 12.5 62.5 22.5 77.5 12.5 20 12.5 52.5
13 15 57.5 12.5 40 17.5 77.5 12.5 65 12.5 60 15 65 12.5 40 25 42.5
14 20 35 15 40 12.5 52.5 22.5 45 20 25 20 45 12.5 25 17.5 75
15 12.5 15 20 52.5 17.5 45 10 25 20 65 12.5 25 17.5 72.5 15 37.5
16 25 70 12.5 20 15 30 20 47.5 10 20 17.5 47.5 17.5 35 12.5 45
17 15 22.5 12.5 52.5 12.5 25 17.5 22.5 12.5 35 10 30 25 85 17.5 57.5
18 12.5 30 10 65 15 22.5 15 50 12.5 20 12.5 55 15 22.5 22.5 55
19 17.5 30 15 10 15 65 15 80 25 25 15 80 12.5 20 15 75
20 12.5 65 17.5 40 15 25 20 72.5 22.5 70 17.5 67.5 17.5 52.5 12.5 65
21 12.5 47.5 15 20 12.5 75 15 40 20 60 15 22.5 15 22.5 17.5 25
22 20 25 12.5 35 12.5 60 22.5 65 15 40 17.5 65 27.5 35 20 30
23 10 80 15 65 22.5 35 12.5 45 12.5 25 12.5 30 25 25 20 60
24 15 27.5 12.5 40 12.5 37.5 10 35 12.5 50 10 37.5 20 65 17.5 70
25 15 60 12.5 45 15 25 10 42.5 12.5 17.5 15 47.5 15 22.5 15 47.5
26 12.5 75 20 80 15 77.5 15 20 15 62.5 12.5 20 15 60 15 22.5
27 10 30 17.5 30 12.5 72.5 25 37.5 22.5 25 30 42.5 20 62.5 25 35
28 10 55 10 40 12.5 62.5 20 22.5 12.5 35 20 22.5 12.5 70 15 25
29 12.5 40 20 17.5 12.5 35 30 62.5 17.5 22.5 30 55 12.5 52.5 12.5 47.5
30 10 15 17.5 45 15 57.5 15 40 12.5 75 12.5 40 22.5 25 22.5 35
Avg. 15.00 44.08 15.75 45.67 15.17 46.08 16.17 48.25 14.42 46.00 15.42 47.00 16.92 47.08 17.00 47.17
S.D. 3.99 21.26 4.79 17.43 3.28 17.58 5.24 16.15 4.14 20.81 5.30 16.33 4.72 20.80 3.79 16.93
10mM SA 
(no pulses)
10mM SA  
750 V/cm
AA (pH4.40) 
(no pulses)
AA (pH4.40) 
750 V/cm
Untreated 
Cells
PBS (no 
pulses)
10mM ASA 
(no pulses)
10mM ASA  
750 V/cm
 
